These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 22676371)

  • 1. Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder.
    Soeiro-de-Souza MG; Dias VV; Figueira ML; Forlenza OV; Gattaz WF; Zarate CA; Machado-Vieira R
    Acta Psychiatr Scand; 2012 Nov; 126(5):332-41. PubMed ID: 22676371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lithium, Stress, and Resilience in Bipolar Disorder: Deciphering this key homeostatic synaptic plasticity regulator.
    Machado-Vieira R
    J Affect Disord; 2018 Jun; 233():92-99. PubMed ID: 29310970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers.
    Manji HK; Chen G
    Mol Psychiatry; 2002; 7 Suppl 1():S46-56. PubMed ID: 11986995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder.
    Einat H; Manji HK
    Biol Psychiatry; 2006 Jun; 59(12):1160-71. PubMed ID: 16457783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder.
    Shaltiel G; Chen G; Manji HK
    Curr Opin Pharmacol; 2007 Feb; 7(1):22-6. PubMed ID: 17055337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
    Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
    Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
    Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms.
    Won E; Kim YK
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29232923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics.
    Bachmann RF; Schloesser RJ; Gould TD; Manji HK
    Mol Neurobiol; 2005 Oct; 32(2):173-202. PubMed ID: 16215281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness.
    Manji HK; Moore GJ; Chen G
    Biol Psychiatry; 2000 Oct; 48(8):740-54. PubMed ID: 11063971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach.
    Machado-Vieira R; Soeiro-De-Souza MG; Richards EM; Teixeira AL; Zarate CA
    World J Biol Psychiatry; 2014 Feb; 15(2):84-95. PubMed ID: 23998912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients.
    Moore GJ; Cortese BM; Glitz DA; Zajac-Benitez C; Quiroz JA; Uhde TW; Drevets WC; Manji HK
    J Clin Psychiatry; 2009 Apr; 70(5):699-705. PubMed ID: 19389332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis.
    Machado-Vieira R; Manji HK; Zarate CA
    Bipolar Disord; 2009 Jun; 11 Suppl 2(Suppl 2):92-109. PubMed ID: 19538689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder.
    Machado-Vieira R; Zanetti MV; Teixeira AL; Uno M; Valiengo LL; Soeiro-de-Souza MG; Oba-Shinjo SM; de Sousa RT; Zarate CA; Gattaz WF; Marie SK
    Eur Neuropsychopharmacol; 2015 Apr; 25(4):468-73. PubMed ID: 25726893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New understanding of mechanisms of action of bipolar medications.
    Sanacora G
    J Clin Psychiatry; 2008; 69 Suppl 5():22-7. PubMed ID: 19265637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is mania caused by overactivity of central brain-derived neurotrophic factor?
    Tsai SJ
    Med Hypotheses; 2004; 62(1):19-22. PubMed ID: 14728999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology.
    Quiroz JA; Singh J; Gould TD; Denicoff KD; Zarate CA; Manji HK
    Mol Psychiatry; 2004 Aug; 9(8):756-76. PubMed ID: 15136795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: long-term effects on cell survival and transcript stability.
    Chen G; Huang LD; Zeng WZ; K Manji H
    Int J Neuropsychopharmacol; 2001 Mar; 4(1):47-64. PubMed ID: 11343630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder.
    Schloesser RJ; Huang J; Klein PS; Manji HK
    Neuropsychopharmacology; 2008 Jan; 33(1):110-33. PubMed ID: 17912251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
    Manji HK; Bebchuk JM; Moore GJ; Glitz D; Hasanat KA; Chen G
    J Clin Psychiatry; 1999; 60 Suppl 2():27-39; discussion 40-1, 113-6. PubMed ID: 10073385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.